PDCD1 and non-small cell lung carcinoma: Exome sequencing of two independent cohorts of NSCLC patients who have received anti-PD1 therapy showed that the non-synonymous mutational burden was higher in patients with durable clinical benefit (Rizvi et al., 2015).